Add BrightSurf on Google Email

Pharmacists can start patients on road to recovery from opioid use disorder, study shows

A study shows that pharmacies can offer a safe starting point for patients with opioid use disorder, leading to higher rates of retention in treatment. The pharmacy-based model increases access to buprenorphine, a lifesaving medication, for diverse patient populations and promotes racial and economic equity.

SourceBrown University·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJan 11, 2023

How differences in diagnoses of mental disorders might affect clinical research outcomes for antipsychotics

A study from Japan found that variations in psychiatric diagnoses across different cultures can affect the efficacy of antipsychotics in clinical trials. Researchers analyzed data from 28 double-blind randomized trials and found that psychotic features were associated with varying therapeutic responses to antipsychotic medications.

SourceFujita Health University·JournalPsychiatry and Clinical Neurosciences·TypeMeta-analysis·DateJan 10, 2023

A new genetic test improves ovarian cancer treatment

A new genetic test has been developed to identify ovarian cancer patients who benefit from PARP inhibitors, a treatment option with significant improvements in prognosis. The test has been optimized for the Finnish population and is clinically approved, allowing for targeted treatment and reduced adverse effects.

SourceUniversity of Helsinki·Journalnpj Precision Oncology·DateJan 9, 2023

Decoding brain arteriovenous malformations in the Asian population: a Chinese Neurosurgical Journal study

A nationwide registry of AVM patients from 52 hospitals in mainland China investigated the efficacy of different treatments on patient groups. The study found that categorizing treatment strategies based on disease severity is an ideal approach, and a multidisciplinary comprehensive assessment promotes individualized treatment protocols.

SourceCactus Communications·JournalChinese Neurosurgical Journal·TypeExperimental study·DateJan 9, 2023

Cellular messengers improve cancer therapy

Extracellular vesicles from immune cells have been shown to activate the immune system in mice with skin cancer, rendering them sensitive to checkpoint inhibitor therapy. The treatment improved survival rates when used in combination with checkpoint inhibitors.

SourceKarolinska Institutet·JournalCancer Immunology Research·TypeExperimental study·DateDec 22, 2022

Oncotarget | Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients

Researchers found that plasma GH levels are a potential biomarker for predicting treatment outcomes in patients with advanced HCC treated with Atezo/Bev. The study showed significantly superior overall survival and non-significant trend in favor of GH-low patients compared to GH-high patients.

SourceImpact Journals LLC·JournalOncotarget·TypeObservational study·DateDec 22, 2022

UNC health provider ushers in first FDA-approved medication for eosinophilic esophagitis

Dupilumab, an FDA-approved medication, offers new hope for patients with eosinophilic esophagitis, a rising condition in the US. The treatment reduces eosinophil counts and improves symptoms of dysphagia, leading to better endoscopic healing and histologic severity improvements.

SourceUniversity of North Carolina Health Care·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateDec 21, 2022

3D-patient tumor avatars: Maximizing their potential for next-generation precision oncology

The use of 3D-patient tumor avatars (3D-PTAs) is crucial for guiding treatment decisions in precision oncology. These avatars, including patient-derived organoids, 3D bioprinting, and microscale models, can accurately depict a tumor with its microenvironment, enabling the testing and prediction of therapeutic drug efficacy.

SourceTerasaki Institute for Biomedical Innovation·JournalCancer Cell·TypeCommentary/editorial·DateDec 20, 2022

Of mice and men

Researchers from Complexity Science Hub and Medical University of Vienna found that high doses of cholesterol-lowering statins impair bone quality in mice, with a significant increase in osteoporosis risk. The study confirms previous findings on the correlation between statin use and osteoporosis diagnosis in humans.

SourceComplexity Science Hub·JournalBiomedicine & Pharmacotherapy·TypeExperimental study·DateDec 18, 2022

HKUMed discovers a novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus associated immune suppression Leads to potential therapeutic targets

Researchers at HKUMed identified a new type of nasopharyngeal carcinoma associated with EBV and immunosuppression in the tumor microenvironment. Global DNA hypermethylation was found to be a critical step in NPC pathogenesis, while global DNA hypomethylation may lead to immune evasion.

SourceThe University of Hong Kong·JournalEBioMedicine·TypeExperimental study·DateDec 15, 2022

VA’s new “burden-free” study method finds two blood pressure drugs equally effective

A large VA clinical trial found that chlorthalidone (CTD) was not superior to hydrochlorothiazide (HCTZ) for preventing cardiovascular disease or non-cancer death. The study enrolled over 13,500 Veterans with high blood pressure and showed no difference between the two drugs in terms of effectiveness.

SourceVeterans Affairs Research Communications·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateDec 14, 2022

Researchers map deep brain stimulation target for Alzheimer's disease

A recent study suggests that stimulating the intersection of two particular brain networks correlated with better patient outcomes than stimulating nearby sites for patients with Alzheimer's disease. Cognitive improvement was associated with DBS to the direct interface between the fornix and bed nucleus of the stria terminalis.

SourceBrigham and Women's Hospital·JournalNature Communications·TypeRandomized controlled/clinical trial·DateDec 14, 2022

Oncotarget | Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma

Researchers describe results using cladribine-based combination epigenetic and immunotherapy in MCL, achieving an increased overall survival greater than 40 months with durable remissions without relapse for longer than 5 years. The approach is promising in the treatment of MCL and potentially other previously treatment-refractory canc...

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateDec 13, 2022

Experimental cancer therapy shows success in more than 70% of patients in global clinical trials

Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNew England Journal of Medicine·DateDec 10, 2022

Next-generation SERD camizestrant significantly improves progression-free survival vs. fulvestrant in advanced ER+ HER2- breast cancer

The SERENA-2 trial found camizestrant significantly improves progression-free survival versus fulvestrant in patients with estrogen receptor-positive, HER2-negative breast cancer. Camizestrant demonstrates efficacy across various patient populations, including those with ESR1 mutations and prior CDK4/6 inhibitor treatment.

For people with dementia with Lewy bodies, treatment with acetylcholinesterase inhibitors, with or without memantine treatment, appears to be associated with both lower risk of mortality and duration of stay for unplanned hospital admissions for physical

Treatment with acetylcholinesterase inhibitors, with or without memantine, may reduce mortality risk and length of stay for unplanned hospital admissions among individuals with dementia with Lewy bodies. The study analyzed data from the UK to support this association.

SourcePLOS·JournalPLOS Medicine·TypeObservational study·DateDec 6, 2022

New study finds promising treatment for cognitive deficits associated with cholestatic liver disease

A new study found that obeticholic acid can reverse cognitive impairment in patients with cholestatic liver disease, improving short-term memory and restoring brain function. The study used a rodent model of bile duct ligation-induced cholestasis and found that the drug significantly improved cognitive deficits.

SourceElsevier·JournalAmerican Journal Of Pathology·TypeExperimental study·DateDec 6, 2022

New antimalarial drug requires higher doses to cure infection

A new antimalarial drug, tafenoquine, is found to require a higher dose of 450mg to achieve cure rates of 85% compared to the current 300mg dose of 70%. The study suggests that the single-dose tafenoquine is not as effective as optimal primaquine treatment in preventing vivax malaria relapses in all endemic regions.

SourceeLife·JournaleLife·DateDec 6, 2022

NSF funds sixth annual tissue engineering solicitation for research leveraging the ISS National Lab

The NSF is funding projects that utilize the International Space Station (ISS) National Laboratory to advance tissue engineering and mechanobiology research. This solicitation aims to further drug discovery and therapeutic development through space-based research, with potential impacts on regenerative medicine and disease diagnosis.

Aging | Glutaminase inhibitors rejuvenate human skin via clearance of senescent cells: a study using a mouse/human chimeric model

Researchers found that glutaminase inhibitor BPTES selectively eliminates senescent dermal fibroblasts, improving skin aging phenotype by increasing collagen density and cell proliferation. The study suggests BPTES as a potential therapeutic agent for skin aging, offering new treatment options.

SourceImpact Journals LLC·JournalAging-US·TypeExperimental study·DateDec 1, 2022

Multiple sclerosis therapy improves gut flora

Researchers found that dimethyl fumarate treatment increased the proportion of beneficial gut bacteria and reduced pro-inflammatory types, which are associated with MS. The study suggests a potential connection between gut flora and clinical side effects, paving the way for personalized treatment approaches.

SourceUniversity of Basel·JournalGut Microbes·DateDec 1, 2022

Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

The Phase II/III study found that acoziborole has an 18-month treatment success rate of 95% for late-stage patients and 100% for early-stage patients, with no significant safety concerns reported. This breakthrough could lead to the elimination of sleeping sickness through a simplified 'screen-and-treat' approach.

SourceDrugs for Neglected Diseases Initiative·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateNov 30, 2022

Pregnant women’s cannabis usage in legalized US states raises calls for screening

A new national study found pregnant women in legalized US states are far more likely to use cannabis, with a 4.6 times higher rate compared to CBD-only states. The study emphasizes the need for prenatal and primary care providers to screen and counsel patients regarding cannabis use in pregnancy.

SourceTaylor & Francis Group·JournalThe American Journal of Drug and Alcohol Abuse·TypeObservational study·DateNov 29, 2022

Transgender youth, teens more likely to have sleep disorders

A Michigan Medicine-led study reveals that transgender youth are 5.4 times more likely to experience insomnia and three times more likely to suffer from sleep apnea compared to cisgender youth. Gender-affirming therapies may offer a protective effect against worsening sleep health, according to the researchers.

SourceMichigan Medicine - University of Michigan·JournalJournal of Clinical Sleep Medicine·TypeObservational study·DateNov 21, 2022

ADHD medication for amphetamine addiction linked to reduced risk of hospitalization and death

A large registry-based study found lisdexamfetamine to be associated with the lowest risk of hospitalisation and death in people with amphetamine addiction. The medication showed a significant reduction in hospitalisation due to substance use disorder and any cause or death, while benzodiazepine and antidepressant use were linked to po...

SourceKarolinska Institutet·JournalJAMA Psychiatry·DateNov 16, 2022

Promise of better treatment for diabetes in Greenland after discovery of widespread genetic variant

A novel HNF1A gene variant has been found to cause monogenic diabetes, affecting almost seven percent of all cases in Greenland. This discovery may pave the way for precision treatment using tablet therapy with sulphonylurea, offering a simpler and cheaper alternative to insulin.

SourceUniversity of Copenhagen - The Faculty of Health and Medical Sciences·JournalThe Lancet Regional Health - Europe·TypeExperimental study·DateNov 15, 2022

Ankle replacement and fusion demonstrate similar effectiveness for end-stage ankle osteoarthritis

A randomized controlled trial found that both total ankle replacement and ankle fusion improve quality of life and have similar clinical scores in patients with end-stage ankle osteoarthritis. However, TAR is associated with greater wound-healing complications and nerve injuries, while AF is linked to more blood clots and nonunion of t...

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeRandomized controlled/clinical trial·DateNov 14, 2022

Molecular basis of resistance to one of the main treatments for multiple myeloma identified

Researchers at CNIO have identified epigenetic changes, specifically DNA methylation, as a key mechanism behind resistance to proteasome inhibitor drugs in multiple myeloma. This finding suggests that methylation levels in the PSMD5 gene can predict treatment response and potentially reverse resistance.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalClinical Cancer Research·TypeExperimental study·DateNov 7, 2022

‘Click’ chemistry may help treat dogs with bone cancer, MU study finds

Researchers at the University of Missouri have successfully used click chemistry to deliver radiopharmaceuticals specifically to tumors in large dogs with bone cancer, increasing effectiveness and minimizing circulation. This breakthrough could pave the way for click chemistry-based treatments for humans with cancer in the future.

SourceUniversity of Missouri-Columbia·JournalMolecular Pharmaceutics·TypeExperimental study·DateNov 4, 2022

Dartmouth study offers new insights into genetic mutations in autism disorders and points to possible treatments

A Dartmouth study reveals that disruptions in the mTORC1 pathway can rescue neuronal overgrowth and synapse function dysregulated by Pten loss, potentially offering new treatments for autism spectrum disorders. The research team also found that administering Rapamycin to children showed some benefit to symptoms of autism.

SourceThe Geisel School of Medicine at Dartmouth·JournalCell Reports·TypeExperimental study·DateNov 1, 2022

Targeted lung cancer drug shows promise in phase I/II clinical trial

The TRIDENT-1 trial suggests that repotrectinib could be effective for treating ROS1 positive non-small cell lung cancer (NSCLC) in patients who have received other targeted treatments and those who have not. The drug showed promising results, with an objective response rate of 79% in patients not previously treated with a ROS TKI.

Researchers identify specific alterations in the BRAF gene that may affect response to treatment and survival in adult brain cancers

The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.

SourceEuropean Organisation for Research and Treatment of Cancer·TypeRandomized controlled/clinical trial·DateOct 26, 2022

Pressure chamber therapy has been found to be effective in the functional improvement of autism

A Tel Aviv University study shows that pressure chamber therapy can improve social skills and reduce neuroinflammation in the autistic brain. The treatment, which involves high-pressure chambers with oxygen enrichment, was found to increase blood and oxygen supply to the brain, leading to improved brain function and social behavior.

SourceTel-Aviv University·JournalInternational Journal of Molecular Sciences·DateOct 26, 2022

New Journal of Pharmaceutical analysis articles highlight progress in the search for therapies to treat challenging diseases

Studies on 18beta-glycyrrhetinic acid, human islet amyloid polypeptide (hIAPP), and fluoroquinolone derivatives explore new approaches to treating challenging diseases. Researchers aim to develop better therapeutics for liver diseases, which cause almost 2 million deaths worldwide every year.

SourceCactus Communications·JournalJournal of Pharmaceutical Analysis·TypeExperimental study·DateOct 25, 2022